Cardno’s turnaround continues as it delivers on guidance

Published 20-AUG-2018 11:32 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Name: Cardno Limited (ASX:CDD)

Market Capitalisation: $650 million

Opening Share Price: $1.40

Cardno, a professional infrastructure and environmental services consultancy group has recorded EBITDA of $56.2 million for FY18, representing a year-on-year increase of 27.7%.

One of the key takeaways in terms of the company’s financial performance was the substantial growth in operating cash flow which increased to $45.7 million.

This was in line with guidance issued in February, and arguably represents a return to delivering on expectations after the group encountered challenges across its market segments in recent years.

While Cardno’s shares have performed well ahead of this result, increasing circa 20% since mid-July, the consensus 12 month price target of $1.80 suggests there could be more upside to come, particularly if it is perceived to have turned the corner.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

The company continues to face headwinds in some of its areas of operation.

Americas up, Asia-Pacific down

The Americas Engineering and Environmental division performance continued to improve with EBITDA margins expanding from 1.6% to 4.8%.

While this remains below industry average, the division is building positive momentum.

Of course it remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.

The Asia Pacific Engineering division’s EBITDA margins declined from 10.9% to 7.5% driven by the continued wind down of a number of major projects in early fiscal 2018, as well as “project clean up” in APAC North.

The division restructured in the second half with the aim of creating a solid platform for growth going forward.

While management didn’t provide fiscal 2019 guidance, the rhetoric regarding the group’s outlook was positive.

Chairman, Michael Alscher said, “Having completed the company’s restructure, we are now entering a phase of stability and our focus is shifting to incremental growth driven by organic initiatives, business optimisation and disciplined, conservatively funded ‘on-strategy’ accretive acquisitions.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free